BioInvent International AB (OTCPK:BOVNF)
$ 4.7 0 (0%) Market Cap: 268.98 Mil Enterprise Value: 170.35 Mil PE Ratio: 0 PB Ratio: 2.59 GF Score: 59/100

BioInvent International AB at Redeye Fight Cancer Seminar (Virtual) Transcript

Jan 20, 2022 / NTS GMT
Release Date Price: $6.63
Richard Ramanius
Redeye AB - Analyst

Welcome to Redeye's Fight Cancer Day. Now it's time for BioInvent with CEO, Martin Welschof, to present the company. So welcome, Martin.

Martin Welschof
BioInvent International AB - CEO

Good morning, Richard. So shall I just take it ahead?

Richard Ramanius
Redeye AB - Analyst

Yes, please go ahead.

Martin Welschof
BioInvent International AB - CEO

Okay, very well. So good morning, everybody. And as usual, I will start with a couple of introductory slides.

So BioInvent is focusing on translating cancer biology into innovative immuno-oncology therapies. And I will explain that to you a little bit more in detail later. We're based in Lund, Sweden, listed in Stockholm, and currently around 100 employees.

So as I mentioned on the previous slide, so we're pushing ahead with innovative immuno-oncology therapies, which are based on multiple modes of action. We have a broad portfolio, which I will introduce to you later.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot